Sarcopenia, thrombosis, and renal dysfunction dominate cirrhosis complication updates
-
by Kerri Miller
November 5, 2025
-
7 min
6 Key Takeaways
-
1
Sarcopenia affects ~40% of cirrhosis patients, needs ongoing assessment.
-
2
Liver Frailty Index is recommended for evaluating sarcopenia.
-
3
Portal vein thrombosis prevalence in cirrhosis patients is approximately 14%.
-
4
Anticoagulation can lower mortality in PVT cases.
-
5
Hepatorenal syndrome may involve structural kidney damage rather than purely functional issues.
-
6
Ongoing trials (e.g., Liver Hero) may offer future insights on management strategies.
Recent updates on managing three complications related to cirrhosis were shared at the United European Gastroenterology Week in Berlin. Francesca Ponziani emphasized the importance of diagnosing and managing sarcopenia, which affects about 40% of cirrhotic patients, suggesting the liver frailty index as a practical tool. Verena Keitel-Anselmino discussed the differences in portal vein thrombosis management for cirrhotic patients, highlighting treatment approaches such as anticoagulation. Professor Raj Mookerjee presented new insights into hepatorenal syndrome, focusing on the impact of inflammation and structural kidney damage in patients with cirrhosis.
Listen Tab content
